



Matthew H. Mead
Governor

State of Wyoming
Department of Workforce Services
 DIVISION OF WORKERS' COMPENSATION
 1510 East Pershing Boulevard, South Wing
 Cheyenne, Wyoming 82002
<http://www.wyomingworkforce.org>



Joan K. Evans
Director
 Lisa M. Osvold
Deputy Director

PROVIDER BULLETIN

TOPIC: Marinol (dronabinol) Use

Published by Wyoming Workers' Compensation Medical Case Management Unit

December 18, 2013

A Medline search was conducted November 18, 2013. Studies involving cannabinoids not approved in the United States are included.

Summary: Based on the research, the use of Marinol for non-malignant pain will be denied by the Division. Any requests for use by a provider will considered investigational and according to the Wyoming Workers' Compensation Rules & Regulations, Chapter 10, Section 19., (the provider) ...will submit to the Division a comprehensive review of the medical literature. This review will include at least two good prospective, randomized, placebo-controlled, double-blind trials.

References

1. Abrams D, Couey P, Shade S, et al. Cannabinoid-opioid interaction in chronic pain. *Clinical Pharmacology and Therapeutics*. 2011; 90(6): 844 – 851.
2. Beaulieu P. Effects of nabilone, a synthetic cannabinoid, on postoperative pain. *Can J Anesth*. 2006; 53: 769 – 775.
3. Berlach D, Shir Y, Ware M. Experience with the synthetic cannabinoid nabilone in chronic noncancer pain. *Pain Medicine*. 2006; 7(1): 25 – 29.
4. Berman J, Symonds C and Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomized controlled trial. *Pain*. 204; 112: 299 – 306.
5. Bestard J and Toth C. An open-label comparison of nabilone and gabapentin as adjuvant therapy or monotherapy in the management of neuropathic pain in patients with peripheral neuropathy. *Pain Practice*. 2011; 11(4): 353 – 368.
6. Blake D, Robson P, Ho M, et al. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. *Rheumatology*. 2006; 45: 50 – 52.
7. Buggy D, Toogood L, Maric S, et al. Lack of analgesic efficacy of oral delta 9-tetrahydrocannabinol in postoperative pain. *Pain*. 2003; 106: 169 – 172.
8. Campbell F, Tramer M, Carroll D, et al. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. *BMJ*. 2001; 323: 1 – 6.



9. Chen B and Hoffman R. The role of cannabinoids in chronic pain patients remains hazy. *Clinical Pharmacology and Therapeutics*. 2012; 91(6): 972.
10. Frank B, Serpell M, Hughes J, et al. Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomized, crossover, double blind study. *BMJ*. 2008; 336(7637): 199 – 207.
11. Hagenbach U, Luz S, Ghafoor N, et al. The treatment of spasticity with delta 9-tetrahydrocannabinol in persons with spinal cord injury. *Spinal cord*. 2007; 45: 551 – 562.
12. Haroutiunian S, Rosen G, Shouval R, et al. Open-label, add-on study of tetrahydrocannabinol for chronic nonmalignant pain. *Journal of Pain & Palliative Care Pharmacotherapy*. 2008; 22(3): 213 – 217.
13. Iskedjian M, Bereza B, Gordon A, et al. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. *Current Medical Research and Opinion*. 2007; 23(1): 17 – 24.
14. Johnson J, Burnell-Nugent M, Lossignol D, et al. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. *J Pain Symptom Manage*. 2010; 39: 167 – 179.
15. Johnson, J, Lossignol D, Burnell-Nugent M, et al. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. *Journal of Pain and Symptom Management*. 2013; 46(2): 206-218.
16. Karst M, Salim K, Burstein S, et al. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain. *JAMA*. 2003; 290(13): 1757 – 1762.
17. Kraft B, Frickey N, Kaufmann R, et al. Lack of analgesia by oral standardized cannabis extract on acute inflammatory pain and hyperalgesia in volunteers. *Anesthesiology*. 2008; 109: 101 – 110.
18. Langford R, Mares J, Novotna A, et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. *J Neurol*. 2013; 260: 984 – 997.
19. Maida V, Ennis M, Irani S, et al. Adjunctive nabilone in cancer pain and symptom management: a prospective observational study using propensity scoring. *Supportive Oncology*. 2008; 6(3): 119 – 124.
20. Narang, S, Gibson D, Wasan A, et al. Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. *The Journal of Pain*. 2008; 9(3): 254 – 264.
21. Notcutt W, Price M, Miller R, et al. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 ‘N of 1’ studies. *Anaesthesia*. 2004; 59: 440 – 452.
22. Notcutt W, Langford R, Davies P, et al. A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex (nabiximols). *Multiple Sclerosis Journal*. 2012; 18(2): 219 – 228.



23. Nurmikko T, Serpell M, Hoggart B, et al. Sativex successfully treats neuropathic pain characterized by allodynia: a randomized, double-blind, placebo-controlled clinical trial. *Pain*. 2007; 133: 210 – 220.
24. Pini LA, Guerzoni S, Cainazzo MM, et al. Nabilone for the treatment of medication overuse headache: results of a preliminary double-blind, active-controlled, randomized trial. *J Headache Pain*. 2012; 13: 677 – 684.
25. Reynolds, T and Osborn H. The use of cannabinoids in chronic pain. *BMJ case reports*. 2013. DOI: 10.1136/bcr-2013-010417.
26. Rintala D, Fiess R, Tan G, et al. Effect of dronabinol on central neuropathic pain after spinal cord injury. *Am J Phys Med Rehabil*. 2010; 89(10): 840 – 848.
27. Roberts J, Gennings C, Shih M. Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine. *European Journal of Pharmacology*. 2006; 530: 54 – 58.
28. Rog D, Nurmikko T, Friede T, et al. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. *Neurology*. 2005; 65: 812 – 819.
29. Rog D, Nurmikko T, and Young C. Oromucosal delta 9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label 2-year extension trial. *Clinical Therapeutics*. 2007; 29(9): 2068 – 2079.
30. Rudich Z, Stinson J, Jeavons M, et al. Treatment of chronic intractable neuropathic pain with dronabinol: case report of two adolescents. *Pain Res Manage*. 2003; 8(4): 221 – 224.
31. Selvarajah D, Emery C, Gandhi R, et al. Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy. *Diabetes Care*. 2010; 35(10): 128 – 130.
32. Serpell M, Notcutt W, Collin C. Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis. *J Neurol*. 2013; 260: 285 – 295.
33. Skrabek R, Galimova L, Ethans K, et al. Nabilone for the treatment of pain in fibromyalgia. *The Journal of Pain*. 2008; 9(2): 164 – 173.
34. Svendsen K, Jensen T and Bach F. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomized double blind placebo controlled crossover trial. *BMJ*. 2004; 329(7460): 253 – 260.
35. Toth C, Mawani S, Brady S, et al. An enriched-enrollment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain. *Pain*. 2012; 153: 2073 – 2082.
36. Turcotte D, Le Dorze J-A, Esfahani F, et al. Examining the roles of cannabinoids in pain and other therapeutic indications: a review. *Expert Opin Pharmacother*. 2010; 11(1): 17 – 31.
37. Wade D, Collin C, Stott C, et al. Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. *Multiple Sclerosis*. 2010; 16(6): 707 – 714.



38. Weber J, Schley M, Casutt M, et al. Tetrahydrocannabinol (delta 9-THC) treatment in chronic central neuropathic pain and fibromyalgia patients: results of a multicenter survey. *Anesthesiology Research and Practice*. 2009. Article ID 827290.
39. Wissel J, Hayden T, Muller J, et al. Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain. *J Neurol*. 2006; 253: 1337 – 1341.
40. Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicenter randomized placebo-controlled trial. *The Lancet*. 2003; 362: 1517 – 1526.
41. Zajicek J, Hobart, J, Slade A, et al. Multiple Sclerosis and Extract of Cannabis: results of the MUSEC trial. *Journal of neurology, neurosurgery, and psychiatry*. 2012; 83(11): 1125 – 1132.

